AbCellera and IGM Biosciences Announce Multi-Year Antibody Discovery Collaboration
“We believe that AbCellera’s technology will assist us in rapidly identifying the best antibodies against a large number of agonist targets, as well as other historically difficult targets, for both oncology and immunology applications,” said
“We believe partnerships like these, which connect breakthrough science with the teams and technologies needed to move forward quickly, are essential in expediting new therapeutic approaches against complex diseases,” said
AbCellera sources, searches, decodes and analyzes natural immune responses to identify antibodies for next-generation therapeutics. A modern operating system for antibody discovery, the platform integrates patented and proprietary technologies to advance the development of existing and new biological modalities, from monoclonal, multi-specific, and single-domain antibodies, to bioconjugates, gene-encoded biologics, and cell therapies. IGM’s proprietary platform expands upon the inherent characteristics of IgM and IgA antibodies and is designed to enable the rapid development of engineered therapeutic antibodies. IGM’s technology allows it to create IgM and IgA antibodies with higher affinity and avidity than naturally occurring IgM and IgA antibodies, and is designed to overcome the historical difficulties in recombinantly expressing and manufacturing IgM and IgA antibodies.
AbCellera is a privately held technology company with an antibody discovery platform that searches and analyzes natural immune systems to find antibodies that can be used to prevent and treat disease. AbCellera’s technology, which combines high-throughput microfluidics, hyper-scale data science, machine learning, bioinformatics, and genomics, identifies new drugs and aims to reduce the time it takes to bring treatments to the clinic. AbCellera's partners include leading biotechnology companies, global health organizations, and many of the top 10 biopharmaceutical companies. For more information, visit www.abcellera.com.
IGM Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements, including statements relating to IGM’s plans, expectations and forecasts and to future events. Such forward-looking statements include, but are not limited to, the potential of, and expectations regarding, the collaboration with AbCellera; the nature and scope of such collaboration; the capabilities of the Company’s technology, its IgM and IgA technology platform and AbCellera’s technology, both generally and specifically with respect to discovery, development, and manufacture of antibodies; the potential safety and efficacy of such antibodies; and statements by IGM’s CEO and AbCellera’s President and CEO. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially, including but not limited to: termination of the collaboration arrangement; IGM’s ability to demonstrate the safety and efficacy of any antibodies developed in connection with the collaboration; IGM’s ability to successfully manufacture such antibodies; IGM’s ability to successfully and timely advance any antibodies through preclinical studies and clinical trials; the risk that all necessary regulatory approvals cannot be obtained; the risk that the potential benefits of the collaboration and these efforts do not outweigh their costs; potential delays and disruption resulting from the COVID-19 pandemic and governmental responses to the pandemic on the collaboration and related efforts; IGM’s early stages of clinical drug development; risks related to the use of engineered IgM antibodies, which is a novel and unproven therapeutic approach; IGM’s ability to obtain additional capital to finance its operations, if needed; uncertainties related to the projections of the size of patient populations suffering from the diseases IGM is targeting; IGM’s ability to obtain, maintain and protect its intellectual property rights; developments relating to IGM’s competitors and its industry, including competing product candidates and therapies; general economic and market conditions; and other risks and uncertainties, including those more fully described in IGM’s filings with the
Kevin Heyries, Ph.D.
IGM Biosciences Contact:
Source: IGM Biosciences